Acrivon Therapeutics (ACRV) is a precision oncology company that has seen significant progress across its proprietary Acrivon Predictive Precision Proteomics (AP3) platform in 2024.Acrivon Therapeutics achieved statistically significant prospective validation of its AP3 patient selection approach via its ACR-368 OncoSignature assay. This assay demonstrated an ability to identify ovarian and endometrial patients sensitive to ACR-368 monotherapy.Its lead pipeline candidate, ACR-368/prexasertib, a CHK1/2 inhib ...